Biological Anti-IL-5/IL-5R Therapeutics for Chronic Obstructive Pulmonary Disease (COPD) with Specific Treatable Traits: A Real-World Retrospective Analysis
Forest Day de Larrañaga,Alexandre Joubert,Isabelle Drouin,Isabelle Ouellet,Pei Zhi Li,Bryan Ross,Carolyn Baglole,Jean Bourbeau
DOI: https://doi.org/10.2147/copd.s438153
2024-01-18
International Journal of COPD
Abstract:Forest Day de Larrañaga, 1, 2 Alexandre Joubert, 3 Isabelle Drouin, 3 Isabelle Ouellet, 3 Pei Zhi Li, 1 Bryan A Ross, 1– 3 Carolyn J Baglole, 1, 2 Jean Bourbeau 1– 3 1 Research Institute of McGill University Health Centre, Montreal, Quebec, Canada; 2 Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada; 3 COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada Correspondence: Jean Bourbeau, Respiratory Epidemiology and Clinical Research Unit, Research Institute of the McGill University Health Centre, 5252 De Maisonneuve, room 3D.62, Montreal, QC, H4A 3S5, Canada, Email Introduction: We describe the use of anti-IL-5 monoclonal antibodies from a COPD clinic, a source other than traditional clinical trials. The objectives were to characterize the patient subgroup prescribed anti-IL-5 monoclonal antibodies and to report potential benefits. Methods: This is a retrospective case series study of 17 patients treated in a COPD subspecialty clinic. All patients had a diagnosis of COPD (post-bronchodilator FEV1/FVC < 0.7) and had been prescribed an anti-IL-5 biologic for at least 8 months. Acute exacerbations of COPD (AECOPDs) were collected as reported in electronic medical records. Results: All patients (17) enrolled were treated with biologics for ≥ 8 months, and 13 (76%) for ≥ 1 year. Patients were characterized by severe disease traits, FEV1 < 50% predicted, recurrent exacerbations (3.5 moderate-to-severe AECOPDs in the year before treatment), high peripheral blood eosinophil counts (≥ 250 cells/μL in the previous year), all on inhaled triple therapy, and only 1 patient with a diagnosis of asthma prior to smoking. There was a statistically significant decrease in the exacerbation rate compared with baseline after 8 and 12 months of anti-IL-5 treatment, respectively, yielding the equivalent of a 2– 3x reduction in exacerbation rate. Absolute FEV1 decreased, and the decline in FEV1 % of predicted reached statistical significance (p< 0.05); CAT score improved (p< 0.05). Discussion: This real-world evidence data aligns with existing studies suggesting the potential benefit of anti-IL-5 treatment for specific patients with COPD and therefore advocates for further investigation of RCTs on the use of anti-IL-5 biologics for well-characterized patients with COPD. Keywords: COPD, biologics, anti-IL5 therapy, blood eosinophil count, RWE, RWD Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease with a possible common feature across phenotypes of frequent and severe acute exacerbations of COPD (AECOPDs). AECOPDs are detrimental to overall health status, and can lead to accelerated deterioration of lung structure, extended or recurrent hospitalizations, and premature death. 1 Moreover, AECOPDs tend to present in clusters, such that the strongest predictor of an AECOPD is a recent history of adverse lung events. 1 Recent randomized clinical trials (RCTs) have shown that individuals with moderate or severe disease who are at high risk of AECOPD benefit from being treated with single inhaler triple therapy. 2,3 This is the basis for the recommendations that these patients be treated with single inhaler triple therapy because of its many proven benefits, including the reduction of moderate and severe AECOPDs and most importantly, a significant reduction in mortality. 4 There is a need to better define patient characteristics for personalizing interventions beyond optimal inhaled therapy for those who continue to experience exacerbations and to further improve patient outcomes. Among other potential therapies, there has been increased interest in the potential role of biological treatments (so-called 'biologics'). Though RCTs have failed to show efficacy of biologics such as anti-IL-5 for relatively non-specific COPD cohorts, 5 post-hoc analysis has identified a subpopulation of patients with COPD with an eosinophilic phenotype for whom this therapy could be effective in reducing annual moderate and severe exacerbations. 6 Furthermore, anti-IL-5 biologics may also decrease oral corticosteroid use in patients with COPD as recently shown in a retrospective case series. 7 Collectively, these studies suggest that biological therapies could be impactful as personalized interventions to reduce AECOPDs and improve health status in COPD patients with demonstrated high peripheral blood eosinophil counts and severe disease traits. More research is required to investigate this therapeutic possibility, including data from real-life clinical practice, which would all -Abstract Truncated-
respiratory system